IBIO
iBio·NASDAQ
--
--(--)
--
--(--)
IBIO fundamentals
iBio (IBIO) Revenue Breakdown: Q3 2022 Business & Regional Performance
iBio (IBIO) reported total revenue of 1.94M USD in Q3 2022, with its core business segment Biopharmaceuticals contributing 134.69%. Regionally, United States remained the largest market, accounting for 100.00% of total revenue. Explore iBio's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
iBio (IBIO) reported total revenue of 1.94M USD in Q3 2022, with its core business segment Biopharmaceuticals contributing 134.69%. Regionally, United States remained the largest market, accounting for 100.00% of total revenue. Explore iBio's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
By Business
No Data
By Region
No Data
You can ask Aime
What were the key takeaways from iBio's earnings call?What is iBio's latest dividend and current dividend yield?What is the revenue and EPS growth rate for iBio year over year?What factors drove the changes in iBio's revenue and profit?What guidance did iBio's management provide for the next earnings period?What were the key takeaways from iBio’s earnings call?What is iBio's gross profit margin?Did iBio beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
